Combination strategies of immunotherapy in breast cancer
Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
26 Oct 2018
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer
Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA
26 Oct 2018
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic pr...
Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah
25 Oct 2018
The standard of care and progress so far with PARP inhibitors for ovarian cancer
Dr Susana Banerjee - The Institute of Cancer Research, London, UK
25 Oct 2018
Comment on the Every Woman Study
Clara MacKay - World Ovarian Cancer Coalition, Canada
24 Oct 2018
ESMO 2018: Highlights
Prof Gordon McVie , Will Davies
22 Oct 2018
The past, present and future of treating ovarian cancer
Dr Susana Banerjee - The Institute of Cancer Research, London, UK
21 Oct 2018
Comment on SOLO-1 for advanced ovarian cancer
Dr Jonathan Ledermann - University College London, London, UK
21 Oct 2018
Olaparib improves progression free survival up front in ovarian cancer
Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA
21 Oct 2018
Preventing ovarian cancer through early excision of tubes and late ovarian remov...
Dr Ranjit Manchanda - Barts Cancer Institute, London, UK
27 Jul 2018
Population-wide testing for cancer-associated mutations
Dr Ranjit Manchanda - Barts Cancer Institute, London, UK
27 Jul 2018
Should HIPEC be part of standard care in the UK?
Dr Ranjit Manchanda - Barts Cancer Institute, London, UK
27 Jul 2018
